SWIFT* k+ reduction AFTER ONE HOUR1,2
Sustained k+ control FOR UP TO ONE YEAR
WHEN USED AS MAINTENANCE THERAPY**1
New, highly-selective LOKELMATM (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients1
*In an emergency situation, standard of care should be used in line with local or national guidelines
** Clinical trials with LOKELMA have not included exposure longer than one year.
GB-17626 June 2019